CMP
PYXS icon

Coston McIsaac & Partners’s Pyxis Oncology PYXS Stock Holding History

Coston McIsaac & Partners’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30
Closed – – 814
2024
Q4 		$0 Hold
30
– – ﹤0.01% 813
2024
Q3 		$0 Hold
30
– – ﹤0.01% 803
2024
Q2 		$0 Hold
30
– – ﹤0.01% 785
2024
Q1 		$0 Hold
30
– – ﹤0.01% 766
2023
Q4 		$0 Sell
30
-114
-79% -$195 ﹤0.01% 766
2023
Q3 		$0 Hold
144
– – ﹤0.01% 779
2023
Q2 		$0 Sell
144
-239
-62% -$758 ﹤0.01% 830
2023
Q1 		$1K Buy
+383
New +$765 ﹤0.01% 763

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Coston McIsaac & Partners's PYXS Position: Q1 2025 in Review

Coston McIsaac & Partners sold out of Pyxis Oncology (PYXS) in Q1 2025, closing a stake of 30 shares.

Coston McIsaac & Partners first reported a position in PYXS in Q1 2023 and held it in 8 quarters. The position peaked at $1K in Q1 2023. 88 funds tracked by Wall St. Rank hold PYXS as of Q1 2025.

  • Coston McIsaac & Partners reported no remaining Pyxis Oncology position as of Q1 2025 after selling out during the quarter.
  • Coston McIsaac & Partners sold 30 Pyxis Oncology shares in Q1 2025.
  • Coston McIsaac & Partners first reported a position in Pyxis Oncology in Q1 2023 and held it in 8 quarters.
  • Coston McIsaac & Partners's Pyxis Oncology position peaked at $1K in Q1 2023.
  • 88 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2025.

Based on Coston McIsaac & Partners's 13F filing for Q1 2025, filed 13 May 2025.